An observational study in Systemic Mastocytosis, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Mayo Clinic · Observational
Among 33 studies in Mastocytosis, Systemic with a site in United States — 7 open to participants now, 10 under way, 1 of them phase 3. Mastocytosis, Systemic · United States.
Among the 33 studies in Mastocytosis, Systemic with a site in United States, this one is one of 2 that started in 2026, is one of 9 observational ones, and was the 33rd registered.
56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.
Browse Mastocytosis, Systemic studies →7 of the 33 studies in Mastocytosis, Systemic with a site in United States are open now. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
Foundation For Rare Disease Research · Sites in United States
Ages 12–75 · Healthy volunteers
Blueprint Medicines Corporation · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
Cogent Biosciences, Inc. · Sites in United States, Australia, Austria and 11 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 2
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 155 across 18 observational studies indexed under Mastocytosis, Systemic.
Median enrollment 86 across the 23 interventional studies, 150 across the 9 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,270 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Mayo Clinic has 2 studies filed under Mastocytosis, Systemic — fewer than ten, so there is no comparison to draw.
5 of the studies in Mastocytosis, Systemic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05362773MacroGenicsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | 2026-11 |
| NCT06327685H. Lee Moffitt Cancer Center and Research InstituteAvapritinib With Decitabine in Patients With SM-AHN | 2027-03 |
| NCT03731260Blueprint Medicines Corporation(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | 2027-06-23 |
| NCT06210698Foundation For Rare Disease ResearchAngioedema Biomarker Research Study | 2027-07-31 |
| NCT07757893Mayo ClinicPrecision Medicine for Indolent Systemic Mastocytosis (PRISM) | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Mastocytosis, Systemic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.
Participants will be identified from Mayo Clinic and Mayo Clinic Health System clinical populations, including individuals actively followed for systemic mastocytosis, and may be approached during routine clinical visits, through electronic health record review, by telephone, text message, electronic health record (EHR) portal message, or through participant-initiated contact via the study website.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 years and older with a diagnosis of indolent systemic mastocytosis who meet eligibility criteria will complete prospective symptom, electronic patient reported outcomes (ePRO), quality of life (QOL) assessments, wearable, environmental exposure, and biospecimen collection over the study period.
Participant Completion Rate at 12 Weeks
Proportion of enrolled participants who remain in the study and complete the 12 weeks of sample and data collection.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.